AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Krystal Biotech Reports Strong 2025 Financials, $955M in Cash Reserves, and Expansion Plans for Rare Disease Therapies.
ByAinvest
Monday, Jan 12, 2026 12:17 am ET1min read
Krystal Biotech reported preliminary unaudited financial results for 2025, with VYJUVEK revenue expected to reach $388-389 million and cash reserves at $955 million. The company is advancing a pipeline of rare disease therapies and plans to have at least four marketed medicines by 2030, while maintaining profitability and investing in broader programs. For 2026, Krystal anticipates combined non-GAAP R&D and SG&A expenses between $175 million and $195 million.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc's editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet